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Abstract
Objective: We assessed the effect of HIV status disclosure on retention in care from initiation of antiretroviral therapy (ART)
among HIV-infected children aged 10 years or more in Cote d’Ivoire, Mali and Se ´ne ´gal.
Methods: Multi-centre cohort study within five paediatric clinics participating in the IeDEA West Africa collaboration. HIV-
infected patients were included in this study if they met the following inclusion criteria: aged 10–21 years while on ART;
having initiated ART$200 days before the closure date of the clinic database; followed $15 days from ART initiation in
clinics with $10 adolescents enrolled. Routine follow-up data were merged with those collected through a standardized ad
hoc questionnaire on awareness of HIV status. Probability of retention (no death or loss-to-follow-up) was estimated with
Kaplan-Meier method. Cox proportional hazard model with date of ART initiation as origin and a delayed entry at date of
10th birthday was used to identify factors associated with death or loss-to-follow-up.
Results: 650 adolescents were available for this analysis. Characteristics at ART initiation were: median age of 10.4 years;
median CD4 count of 224 cells/mm
3 (47% with severe immunosuppression), 48% CDC stage C/WHO stage 3/4. The median
follow-up on ART after the age of 10 was 23.3 months; 187 adolescents (28.8%) knew their HIV status. The overall probability
of retention at 36 months after ART initiation was 74.6% (95% confidence interval [CI]: 70.5–79.0) and was higher for those
disclosed compared to those not: adjusted hazard ratio for the risk of being death or loss-to-follow-up=0.23 (95% CI: 0.13–
0.39).
Conclusion: About 2/3 of HIV-infected adolescents on ART were not aware of their HIV status in these ART clinics in West
Africa but disclosed HIV status improved retention in care. The disclosure process should be thus systematically encouraged
and organized in adolescent populations.
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Introduction
In West Africa, children infected with HIV through mother-to-
child transmission, once diagnosed and in care, live longer and
reach adolescence, because of greater access to antiretroviral
therapy (ART) drugs observed in West Africa in the past decade
[1,2]. Adolescence is characterized by remarkable physical, mental
and social changes and difficulties. In addition, adolescents,
starting sexual activity are at high risk of HIV acquisition and
transmission in areas of generalized epidemic [2].
Emotional and behavioural disorders have been described in
Africa throughout adolescence. Musisi et al reported that, among
82 Ugandan HIV-infected adolescents, 98% were orphans, 51%
reported psychological distress and 17% attempted suicide [3]. In
a study in Zambia, about 40% of 127 HIV-infected adolescents
reported mental health problems [4].
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[5,6,7] such as in a US series where it was observed in 67% of 154
adolescents, mainly associated with the lack of adherence and
suboptimal ART use [8]. Treatment adherence may be one of the
critical issues for therapeutic long-term success in adolescents.
Problems of adherence were indeed noticed, not only in an
American study, in 40% out of 396 adolescents [9], but also in
Southern Africa in more than 60% of the adolescents surveyed [5].
Disclosed HIV status has been identified as one of the factors
associated with better adherence [10,11]. However, the prevalence
of disclosure in children and adolescents varies by setting and
according to the age of the patients, from 13 to 60% in children
between 5 to 17 years from Asia or Southern-Eastern Africa
[4,12,13,14,15,16,17,18,19]. While also essential for the secondary
prevention of HIV transmission, disclosure for adolescents may
accentuate emotional and behavioural disorders, familial conflicts
or social stigma perception and may thus jeopardize confidentiality
[20,21]. HIV status disclosure of youths represents a challenge for
the family and for medical staff [22,23,24].
The disclosure process in adolescents is poorly documented
outside Southern Africa and it is not known whether it may
influence their clinical response to ART. The main objectives of
this study were thus (1) to estimate the frequency of HIV disclosure
in an adolescent population in West African settings; (2) to assess
the effect of disclosed HIV status to HIV-infected adolescents on
ART clinical outcomes (death and loss-to-follow-up).
Methods
Ethics statement
The IeDEA West Africa collaboration project received ethical
approval from the Bordeaux University Hospital Institutional
Review Board. A waiver for informed consent was given as this
data was collected from routine patients’ charts.
Study design
We conducted a retrospective study nested in a multi-centre
prospective cohort network of paediatric clinics participating in the
International epidemiological database to Evaluate AIDS (IeDEA)
West Africa collaboration (http://mereva.net/iedea). This collab-
oration was initiated in 2006 and currently involves 11 pediatric
HIV/AIDS clinics spread over seven countries: Benin, Burkina
Faso, Co ˆte d’Ivoire, Ghana, Mali, Senegal and Togo [25].
However, as the centers from Co ˆte d’Ivoire, Mali and Senegal
followed-up about 90% of all adolescents from this collaboration,
the present study was therefore restricted to these countries,
including three centers in Abidjan, Co ˆte d’Ivoire (the pediatric
ward of the Teaching Hospital of Yopougon, the Centre Inte ´gre ´
de Recherches Biocliniques (CIRBA), the Centre de Prise en
charge de Recherche et de Formation (CePReF); the pediatric
ward of Gabriel Toure Hospital in Bamako, Mali and the pediatric
ward of Albert Royer Hospital in Dakar, Se ´ne ´gal.
Study sample
In each pediatric clinic participating in the IeDEA West Africa
collaboration, clinical forms were available for recording HIV
activities and an electronic database for data entry. All HIV-
infected children (positive viral load test at ,18 months or positive
serology at $18 months) aged ,21 years with documented gender
and antiretroviral drug regimen were included. These HIV-
infected children were typically seen in clinics at least every three
months, and their CD4 counts were measured twice a year to
monitor their immunological response to ART. Routine viral load
monitoring was not available in most sites.
The inclusion criteria in the present study were:
– Aged 10–21 years during follow-up while on ART
– Followed-up in a paediatric clinic with $10 adolescents in care
– Having initiated ART $200 days before the closure date of the
local database
– Followed-up$15 days from ART initiation.
Adolescence is usually defined by the World Health Organiza-
tion (WHO) [26] as the period between childhood and adult age,
from 10 to 19 years. In our study we extended the age upper limit
to 21 years as this is the age of legal majority in Co ˆte d’Ivoire (18
in the other countries).
Strategies of HIV disclosure varied according to sites: in Dakar,
focus group and patient education were proposed. In Bamako, a
monthly follow-up for the adolescent and his/her parents was
conducted by a dedicated physician. The three sites from Abidjan
had a team of psychologists providing psychological support to the
children and the caregivers, not only for disclosure, but also for
adherence for instance. However, none of the sites had developed
local guidelines.
Data collection
In the context of the IeDEA West Africa collaboration, baseline
and follow-up data were recorded in the local databases
computerized in the participating clinics and merged together in
a larger database (Microsoft Office Access 2003). All data were
anonymized using a unique, confidential identification number.
The following data from patients meeting inclusion criteria were
extracted from the pediatric central database:
– Demographic data: date of birth, gender
– ART regimen: type and date of initiation
– Biological and clinical data at treatment initiation (or 200 days
before): CD4 cell count and CD4 percentage, haemoglobin,
CDC and WHO clinical stage
– Outcomes: Transfer out, death, CD4 CD4 cell count and CD4
percentage and dates of events
A standardized form was created to extract study specific data
from the medical, psychological and social charts available in the
patient’s files. This form was prepared based on literature review
and discussions between the investigators and the staff in charge of
disclosure in each clinic. The questionnaire was tested in Abidjan
to reach a final version before full implementation in May 2010. It
included the following information:
– Own HIV status disclosed to the adolescent (‘‘Is the adolescent
informed about his/her HIV status?’’), and if so,
# date of disclosure
# Persons involved: physician, social worker, psychologist…
# Conditions of disclosure: planned or not, timing (before or
after ART initiation)
# Immediate reaction to disclosure
– Individual situation at disclosure or at closure date: living,
schooling
The questionnaire was completed by physicians, psychologists
or social workers involved in each clinic. Data specific to the study
were computerized on each site using Epi-Info software version
5.3.2 and then were merged in the IeDEA West Africa central
office in Bordeaux.
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To compare the characteristics of adolescents included or not in
the analyses, as well as of those with disclosed HIV status or not,
Fisher and Chi-square tests and Kruskal-Wallis tests were used for
qualitative variables and quantitative variables, respectively.
Probability of death, loss-to-follow-up, and retention in HIV
care (patients neither dead nor lost-to-follow-up) was estimated
with the Kaplan-Meier method overall and according to the HIV
disclosure status. Loss-to-follow-up was defined as the last contact
before 21 years of age recorded $200 days before the closure date
of local database, with no mention of transfer out or death.
The end point was defined as the date of death, loss-to-follow-
up, 21
st birthday or last contact before the closing date of the
database (04/01/2008 for the Teaching Hospital of Yopougon,
05/11/2008 for the CIRBA, 05/11/2008 for theCePReF , 20/
12/2008 for the Bamako Hospital, 19/06/2009 for the Dakar
Hospital.
To assess factors associated with these risk functions, Cox model
was used, with date of ART initiation as origin, censoring at the
closure dates of the local databases and with delayed entry at date
of 10th birthday for those who initiated ART before 10. All
analyses used the center as a cluster variable, taking into account
the correlation of the observations within a same center. Missing
data (MD) were treated as specific categories except for the
variable of interest (disclosed HIV status). Patients with missing
data on this variable were excluded.
All analyses were performed with SAS software 8.2 (USA). All
p-values were two-tailed. A p-value,0.05 was considered as
statistically significant. Variables with a p,0.20 in univariate
models were examined in multivariate models and selected
thereafter using a backward stepwise procedure. Hazard ratios
(HR) and their 95% confidence intervals (CIs) were produced.
Results
Sample description
The inclusion criteria were met by 669 adolescents (Figure 1)
from the five centers selected. Nineteen had missing data on HIV
disclosure status and were described separately. Thus, 650
adolescents remained in the analysis, representing 93.8% of the
selected population (Figure 1). They had a median age at ART
initiation of 10.4 years, a median CD4 count of 224 cells/mm
3
(46.9% with severe immunosuppression; i.e. CD4,200 cells/
mm
3; 68 with MD), a median haemoglobin of 10.0 g/dL (4.8%
with severe anaemia; i.e. blood haemoglobin,6.9 g/dL; 93 MD)
and 277 (48.1%) were stage 3 or 4/C at ART initiation (73 MD)
(Table 1). Most of them (n=447; 68.8%) started with a non
nucleosidic (NNRTI)-based ART regimen.
About 55% of the adolescents (n=360) started ART after the
age of ten. Over a median 35.8 months follow-up period from
ART initiation (23.3 months in median from the age of ten), 40
(6.1%) died and 85 (13.1%) were lost-to-follow-up (Table 2). The
median age at the endpoint was 13.1 years.
Overall, 187 (28.8%) adolescents knew their HIV status
(Table 3). Compared to those not disclosed, adolescents with
disclosed HIV status were, at ART initiation:
– Older (median age: 11.9 vs 9.8 years, p,0.0001)
– More often on NNRTI-based ART (76.5% vs. 65.6%,
p=0.007)
– Less often living with their parents (45.9% vs. 57.0%,
p=0.011)
– At similar rate of severe immunodeficiency, clinical stage at
ART initiation, being orphaned of at least one parent and
attending school at the endpoint (p.0.1).
The year of disclosure was known for only 59 adolescents
(31.5%) (Table 3). This variable was poorly reported in the charts
in Abidjan. When known, the median age at disclosure was 15
years (IQR: 14–15; min=11; max=19). At the time of disclosure
or end point, 471 adolescents (72.5%) were known to be orphaned
of at least one parent (biological mother or father) and 330 (50.8%)
were known to live at that time with a parent.
Conditions of the disclosure of the HIV status to the
adolescents
Most of HIV disclosures happened after ART initiation and
were planned (Table 4). The persons involved in this process
varied across the countries. It was mainly conducted by the family,
particularly the mother and the father in Abidjan after an
interview between the latter and the psychologists, while it was
conducted by the health care staff in Bamako and Dakar.
Figure 1. Cohort profile for the adolescent HIV disclosure
study. Pediatric IeDEA West Africa (WADA) Collaboration.
doi:10.1371/journal.pone.0033690.g001
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on retention in care
The overall 36-month probability of retention after ART
initation in this sample aged $10 was 74.6% (95% CI: 70.5–79.0).
It was significantly lower for those whose HIV status was not
disclosed (Figure 2). Overall, the 3-year probability of survival was
92.1% (95%CI: 89.4–95.0) and the probability of not being lost-to-
follow-up was 80.4% (95%CI: 76.5–84.5). Disclosed HIV status
was associated with higher retention in care in multivariate
analysis: adjusted hazard ratio (aHR)=0.23 (95% CI: 0.13–0.39;
p,0.0001) (Table 5).
Description of excluded patients with MD on disclosure
and sensitivity analysis
There were 19 adolescents excluded because of MD on
disclosure status (17 from Abidjan). Three were dead and five
lost to-follow-up by 31 months in median after ART initiation
after the age of ten.
If all patients with missing data were classified as not-disclosed
HIV status, the probability of retention for these patients
decreased to 60.8% (95%CI 55.2–67.1), increasing the difference
acording to the HIV disclosure status. If all patients with missing
data were classified as disclosed HIV positive status, the
probability of retention for these patients increased to 89.7%
(95%CI 84.4–93.9), decreasing the difference between the two
groups but it remained statistically significant, in univariate and
multivariate analyses (aHR=0.28; 95%CI=0.18–0.44).
Discussion
In this multicentered cohort study conducted in West Africa, we
described a large sample of HIV-infected adolescents who started
ART at a median age of 10.4 years. Despite this information was
not documented with reliability in this cohort, it is estimated that
more than 90% of the children/adolescents acquired HIV through
mother-to-child transmission and can be considered as slow
progressors [27]. We observed that about two thirds of HIV-
infected adolescents on ART beyond the age of ten were not
aware of their own HIV status. When the age at disclosure was
known, it was delayed around a median of 15 years. We
demonstrated a beneficial effect of HIV disclosure on retention
in care among adolescents on ART.
Although low, the frequency of disclosed HIV status in our
study was higher than previously reported figures in studies
conducted in Nigeria, Ethiopia, Thailand and India where the
children were younger (mean age=8–9 years) [13,17,18,28] or
Ghana, with a median age of ten [12]. It was similar to other
studies conducted in Uganda and Zambia in children aged 12 in
median [4,11] or Thailand (mean age 9.2 years) [15] but a bit
Table 1. Characteristics of adolescents at ART initiation.
Abidjan (n=403) Bamako (n=174) Dakar (n=73) Overall (n=650)
Variable Unit N Med (IQR) N Med (IQR) N Med (IQR) N Med (IQR)
Age Years 402 10.7 (8.8–12.8) 174 10.0 (8.4–11.7) 73 9.9 (8.7–13.0) 650 10.4 (8.8–12.7)
CD4 cells/mm
3 363 283 (78–529) 173 171 (57–325) 46 121 (19–350) 582 224 (63–424)
Haemoglobin g/dL 356 10.2 (9.0–11.1) 161 9.7 (8.7–10.7) 40 9.0 (7.7–11.0) 557 10 (8.7–11)
Weight kg 357 24 (19–29) 155 20 (17–25) 69 21 (18–27) 581 23 (19–27)
Stage 3&4/C N n (%) 350 107 (30.6) 155 106 (68.4) 72 64 (88.9) 577 277 (48.0)
NNRTI N n (%) 403 271 (67.2) 174 118 (67.8) 73 58 (79.5) 650 447 (68.8)
Pediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral treatment; NNRTI: non nucleoside reverse transcriptase inhibitor;
N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.
doi:10.1371/journal.pone.0033690.t001
Table 2. Follow-up characteristics of adolescents on ART.
Abidjan (n=403) Bamako (n=174) Dakar (n=73) Overall (n=650)
Variable Unit Med (IQR) Med (IQR) Med (IQR) Med (IQR) (min-max)
Follow-up from ART
initiation
Months 36.5 (23.6–38.6) 29.1 (16.6–52.1) 45.8 (24.3–67.0) 35.8 (21.2–39.8)
Follow-up from the
age of 10
Months 24.3 (12.5–36.5) 19.0 (9.8–31.6) 25.4 (14.2–49.0) 23.3 (11.3–36.6)
Age at endpoint Years 13.3 (11.5–15.3) 12.5 (11.2–14.5) 13.8 (11.7–16.5) 13.1 (11.5–15.3)
Death n (%) 19 (4.7) 10 (5.7) 11 (15.0) 40 (6.1)
Mortality incidence
from the age of 10
/1000 pers-month 1.97 2.51 4.49 2.49
Loss-to-follow-up n (%) 45 (11.2) 35 (20.1) 5 (6.8) 85 (13.1)
Pediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral therapy.
N: number; Med: median; IQR: Inter Quartile Range; Min: minimum; Max: maximum.
doi:10.1371/journal.pone.0033690.t002
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years [19]. Indeed, disclosure was often associated with an age.10
or even older [13,17,18,29,30], supporting our observations. In a
qualitative study conducted in South Africa, the age of ten has
been reported by health workers as the most appropriate to start
having discussion regarding HIV infection [31].
In a US perinatally HIV-infected cohort, HIV disclosure was
observed to occur at younger age over time, which may suggest a
decline in the perception of HIV stigma [29]. In this industrialized
country, the social and medical network may have been strengthened,
leading to this condition. In resource-limited settings, despite local
interventions, such as peer support groups, or community organiza-
tions for social support, stigma and fear of negative reactions or
psychosocial outcomes may remain strong barriers to an earlier HIV
disclosure to children [4,12,15,17,22,32,33,34,35].
Conditions of disclosure varied according to settings. In
Abidjan, relatives were encouraged to conduct the disclosure
while the medico-social staff was more involved in the other
countries. In Nigeria, most of the disclosure was conducted by
family, preferably the mother, at home [18]. In Ghana, it was also
mostly conducted by caregivers [12], but among those who had
not disclosed, one-third wanted to defer to the health workers.
Similarly, in Ethiopia, 60% of 193 caregivers interviewed thought
that the doctor was responsible for disclosure [17] and in
Thailand, 50% of the interviewed caregivers reported the need
of assistance from health workers [15]. These findings were
Table 3. Characteristics of adolescents at HIV disclosure or last contact.
Abidjan (n=403) Bamako (n=174) Dakar (n=73) Overall (n=650)
Variable n (%) n (%) n (%) n (%)
Disclosure Yes 127 (31.5) 44 (25.3) 16 (21.9) 187 (28.8)
Known date of disclosure Yes 10/127 (7.9) 40/44 (90.9) 9/16 (56.2) 59/187 (31.5)
Orphanhood No 98 (24.3) 38 (21.8) 14 (19.2) 150 (23.1)
One parent 187 (46.4) 61 (35.1) 35 (47.9) 283 (43.5)
Two parents 100 (24.8) 67 (38.5) 21 (28.8) 188 (28.9)
Unknown 18 (4.3) 8 (4.6) 3 (4.1) 29 (4.5)
Living with parents No 162 (40.2) 84 (48.3) 36 (49.3) 282 (43.4)
Yes 208 (51.6) 86 (49.4) 36 (59.3) 330 (50.8)
Unknown 33 (8.2) 4 (2.3) 1 (1.4) 38 (5.8)
Schooling No 54 (13.4) 31 (17.8) 26 (35.6) 111 (17.1)
Yes 319 (79.2) 108 (62.1) 43 (58.9) 470 (72.3)
Unknown 30 (7.4) 35 (20.1) 4 (5.5) 69 (10.6)
Pediatric IeDEA West Africa (WADA) Collaboration.
N: number.
doi:10.1371/journal.pone.0033690.t003
Table 4. Characteristics of the process of HIV disclosure of adolescents.
Abidjan (n=127) Bamako (n=44) Dakar (n=16) Overall (n=187)
Variable n (%) n (%) n (%) n (%)
Mother involved in disclosure 35 (27.6) 0 (0) 0 (0) 35 (18.7)
Father involved in disclosure 26 (20.5) 1 (2.3) 0 (0) 27 (14.4)
Physician involved in disclosure 4 (3.1) 40 (90.9) 8 (50.0) 52 (27.8)
Psychologist involved in disclosure 6 (4.7) 0 (0) 3 (18.7) 9 (4.8)
Social worker/counsellor involved in disclosure 1 (0.8) 0 (0) 5 (31.2) 6 (3.2
Other* 62 (48.8) 5 (11.4) 2 (12.5) 69 (36.9)
Conditions of the disclosure Planned 67 (52.8) 40 (90.9) 9 (56.2) 116 (62.0)
Not planned 55 (43.1) 0 (0) 5 (31.2) 60 (32.1)
Not known 5 (3.9) 4 (9.1) 2 (12.5) 11 (5.9)
Timing of disclosure Before ART initiation 10 (7.9) 0 (0) 2 (12.5) 12 (6.4)
After ART initiation 107 (84.2) 40 (90.9) 13 (81.2) 160 (85.6)
Not known 10 (7.9) 4 (9.1) 1 (6.2) 15 (8.0)
Pediatric IeDEA West Africa (WADA) Collaboration.
ART: Antiretroviral therapy.
*Consisted in other persons of the family (uncle, aunt, grand-mother, grand-father, adoptive father or mother), persons from foster care shelters or NGOs (n=14),
nobody involved because of reading the notice (n=4).
doi:10.1371/journal.pone.0033690.t004
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account the delayed entry at age of 10 years (n=650). Pediatric IeDEA West Africa Collaboration. * Estimation at 36 months from ART
initiation.
doi:10.1371/journal.pone.0033690.g002
Table 5. Crude and adjusted hazard ratios (HR) with 95% confidence intervals (CI) of risk of death or loss-to-follow-up of
adolescents after ART initiation (n=650).
Crude Adjusted
Variables HR 95%CI p-value aHR 95%CI p-value
Disclosure (ref: no) Yes 0.23 0.13–0.39 ,0.0001 0.23 0.13–0.39 ,0.0001
Gender Male 1.08 0.76–1.55 0.655
CD4,200 cells/mm
3 (ref: no) Yes 1.73 1.17–2.55 0.014 1.65 1.11–2.44 0.017
MD 1.75 0.99–3.08 1.97 1.07–3.62
Severe anaemia (ref: no) Yes 0.74 0.27–2.01 0.363
MD 1.34 0.84–2.01
NNRTI- based regimen (ref: no) Yes 0.87 0.84–1.13 0.461
Stage 3&4/C (ref: no) Yes 1.29 0.88–1.88 0.405
MD 1.07 0.57–2.02
Country (ref: Co ˆte d’Ivoire) Mali 1.78 1.19–2.66 0.014 1.74 1.15–2.64 0.016
Se ´ne ´gal 1.09 0.62–1.93 0.87 0.48–1.57
Pediatric IeDEA West Africa Collaboration.
All analyses used the center as a cluster variable, taking into account the correlation of the observations within a same center.
HR: Hazard ratio.
aHR: adjusted hazard ratio.
MD: missing data.
ART: Antiretroviral therapy.
NNRTI: non nucleoside reverse transcriptase inhibitor.
Severe anemia: haemoglobin#6.9 g/dL.
Severe immunosuppression : CD4,200 cells/mm
3.
doi:10.1371/journal.pone.0033690.t005
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South African setting [31]. In this present study, the sites
implemented different strategies to conduct the disclosure process
(described in the Methods), which could explain, in part, the
differences observed between across the cities in terms of retention.
Also, the investigators of the participating centers were aware of the
recommendations from the French-speaking association called
Grandir [36,37]. However, they faced difficulties not addressed by
these recommendations. For instance, they had problems to manage
the caregivers’ reluctance to disclose or to make understand to the
adolescent what HIV is and its impact on life. They required sharing
field experiences to harmonize process and guide local policy on
HIV disclosure to be conducted inoptimal conditions involving both
adolescents and their caregivers. Recent guidelines proposed by the
World Health Organization underlinedtheabsenceofevidenceasto
who best can disclose to the child his/her HIV status, caregiver or
health care worker with or without specific training [38].
In this large cohort with three-year follow-up, we observed a
relatively low death rate but a quite important loss-to-follow up rate,
similar to a previous report on clinical outcomes in West African
children[25]. Ina study conducted in Uganda, including575patients
starting ART during adolescence, the cumulative survival at 36
months was 90% (95% CI 87.9–93.1) [39]. This figure was similar to
the survival rate found in our study where 55% has initiated ART
after the age of ten. We found that HIV disclosure was associated
with better retention in care as already reported in a Romanian
setting among adolescents with a mean age of 13 years [40].
Several limitations could be discussed in our study. First, the
main limit of this study is its partially retrospective design and the
fact that it relied heavily on the patients’ charts, leading to missing
data and possible information bias. In particular, the HIV
disclosure status was not systematically reported in the patients’
charts. However, the forms were filled in by clinic staff, who knew
the patients and their family environment quite well and could
remember and cross-check who was informed of his/her HIV
status and who was not. Some charts could not be found or used
and were classified as missing data and the corresponding
adolescents were not included in the analyses. Sensitivity analyses,
coding these records either as disclosed HIV status or not disclosed
did not lead to a large variation in our findings.
Second, the HIV disclosure status was reported as a dichotomic
variable, while disclosure is a process evolving over time. Thus
some adolescents may have been categorized as not informed of
their HIV status while they may have been told that they harbour
a virus, but not specifying HIV. Some studies, preferably those
with a qualitative design, specify that some children are partially
disclosed. It refers to the following broad category: ‘‘child not fully
aware of his/her HIV disease but is suspicious, asks questions to
the caregiver about the disease and the drug, and, in many cases,
assumes that the drug is a cure’’ [11]. This status could not have
been taken into account in our study with no qualitative data
recorded. In addition, the age at disclosure was frequently missing
and it was not possible to study this variable as a time-dependant
information in the survival analyses.
Third, some of the adolescent lost-to-follow-up might have been
unreported deaths. We have addressed this possible misclassifica-
tion by specifically retrieving and reviewing every patient’s chart
meeting the definition of loss-to-follow-up in case the charts had
been completed after the closure of the database for this analysis.
Finally, due to the retrospective design, we could not address the
psychosocial effect of disclosure. A cross-sectional study conducted
in New York City demonstrated that Youths (n=196, mean age
12.7 years) with disclosed HIV status were significantly less anxious
than those who had not been told but there were no other
differencesinpsychologicalfunctioning[30].Thisshouldbe verified
in African settings as the caregivers’ fear for negative psychosocial
outcomes is a common barrier to disclose as discussed previously.
In conclusion, most of HIV-infected adolescents on ART in
these West African settings were not aware of their HIV status.
However, our study showed a strong beneficial effect of HIV
disclosure on retention in care after ART initiation beyond the age
of ten. This sample of clinics had initiated different strategies to
carry out the HIV disclosure process in the absence of guidelines
or specific training. Such initiatives need to be promoted and
developed as they may provide individual benefits. For this
purpose, they need to be described, standardized, evaluated and
shared. Also, further studies should look at the effect on other
outcomes such as immunological failure, treatment adherence,
virological progression, viral resistance, but also anxiety, depres-
sion, school performance, family and social relations and sexual
risk behaviours. This would provide deeper understanding of HIV
disclosure process in adolescents in resource limited settings in
order to tailor age-adequate interventions.
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